| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 549.5 | 416.1 |
| Gross profit | 335.1 | 172.4 |
| Profit before tax | -116.1 | -266.4 |
| Net income | -96.1 | -291.1 |
| EPS (diluted, $ a share) | $-2.43 | $-9.01 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +32.1% |
|---|---|
| Gross margin | 61.0% |
| Operating margin | 13.7% |
10-Q filed with the SEC. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Keenova Therapeutics plc: key numbers
- Shares outstanding
- 39.65MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Keenova Therapeutics plc
All →Keenova Therapeutics Insider Goldentree Asset Management LP Buys $13.7M of Stock
Goldentree Asset Management LP bought 150,652 shares of Keenova Therapeutics plc at $89.25 to $91.00 a share (average $90.65) in 2 transactions, worth $13.7M in total between Nov 9, 2026 and Nov 10, 2026. Shares held after the trade: 9,026,195 (+1.4%).
- Value
- $13.7M
- Shares
- 150,652
- Average price
- $90.65
- Holding change
- +1.4%
- Trade date
- Nov 9, 2026 to Nov 10, 2026
Keenova Therapeutics Financial Results
Keenova Therapeutics reported Q3 2026 net sales of $550 million, driven by strong performance from core brands Acthar Gel and XIAFLEX. The company raised its full-year guidance for net sales and Adjusted EBITDA based on higher growth expectations for XIAFLEX and continued demand for Acthar Gel.
- Term
- Q3 2026
“On this day last year, Keenova introduced itself as a new company with a new identity and a bright future. Since that day, we have made significant strategic, commercial, operational, and clinical progress toward fulfilling our goal of becoming a pure-play branded therapeutics company. Our third-quarter 2026 results further demonstrate the consistent progress we are making against that goal.”
Siggi Olafsson, Board Chair and Chief Executive Officer
“In the quarter our core brands, Acthar Gel and XIAFLEX, contributed better-than-expected performance, driven primarily by increased demand and improved operational execution. As a result, we are reiterating our full-year net sales growth outlook for Acthar Gel of 20% to 22% and now expect XIAFLEX net sales to grow 10% to 11% year over year.”
Siggi Olafsson, Board Chair and Chief Executive Officer
Keenova Therapeutics Insider Goldentree Asset Management LP Buys $26.4M of Stock
Goldentree Asset Management LP bought 295,716 shares of Keenova Therapeutics plc at $89.25 a share, worth $26.4M in total between Nov 5, 2026 and Nov 6, 2026. Shares held after the trade: 8,875,543 (+1.7%).
- Value
- $26.4M
- Shares
- 295,716
- Average price
- $89.25
- Holding change
- +1.7%
- Trade date
- Nov 5, 2026 to Nov 6, 2026
Keenova Therapeutics Insider Goldentree Asset Management LP Buys $12.3M of Stock
Goldentree Asset Management LP bought 137,000 shares of Keenova Therapeutics plc at $90.00 a share, worth $12.3M in total on Oct 14, 2026. Shares held after the trade: 8,579,827 (+1.6%).
- Value
- $12.3M
- Shares
- 137,000
- Price
- $90.00
- Holding change
- +1.6%
- Trade date
- Oct 14, 2026
Keenova Therapeutics Insider Goldentree Asset Management LP Buys $42.1M of Stock
Goldentree Asset Management LP bought 463,000 shares of Keenova Therapeutics plc at $91.00 a share, worth $42.1M in total on Sep 24, 2026. Shares held after the trade: 8,442,827 (+5.8%).
- Value
- $42.1M
- Shares
- 463,000
- Price
- $91.00
- Holding change
- +5.8%
- Trade date
- Sep 24, 2026